IFNγ score-based neoadjuvant immunotherapy for stage III melanoma

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Stage III melanoma requires effective neoadjuvant immunotherapy strategies.
• Identifying predictive biomarkers is crucial for optimizing treatment selection.

Purpose of the Study:

• To evaluate interferon gamma (IFNγ)-related gene expression scores as predictive markers for neoadjuvant immunotherapy in stage III melanoma.

Main Methods:

• Analysis of gene expression profiles before and after treatment.
• Correlation of IFNγ-related gene expression scores with treatment response.

Main Results:

• Pre- and post-treatment IFNγ-related gene expression scores demonstrated potential as predictive biomarkers.
• These scores may aid in selecting appropriate neoadjuvant immunotherapy.

Conclusions:

• IFNγ-related gene expression signatures offer a promising approach for personalizing neoadjuvant immunotherapy in stage III melanoma.
• Further validation is warranted to integrate these markers into clinical decision-making.